Site-specific analysis of advanced glycation end products in plasma proteins of type 2 diabetes mellitus patients

被引:29
|
作者
Greifenhagen, Uta [1 ,2 ]
Frolov, Andrej [1 ,3 ]
Blueher, Matthias [4 ]
Hoffmann, Ralf [1 ,2 ]
机构
[1] Univ Leipzig, Inst Bioanalyt Chem, Fac Chem & Mineral, Deutsch Pl 5, D-04103 Leipzig, Germany
[2] Univ Leipzig, Ctr Biotechnol & Biomed BBZ, Deutsch Pl 5, D-04103 Leipzig, Germany
[3] Leibniz Inst Plant Biochem, Dept Bioorgan Chem, Weinberg 3, D-06120 Halle, Germany
[4] Univ Leipzig, Dept Med, Endocrinol, Liebigstr 20, D-04103 Leipzig, Germany
关键词
Advanced glycation end product (AGE); Mass spectrometry; Non-enzymatic modification; Posttranslational modification (PTM); Proteomics; Type 2 diabetes mellitus (T2DM); MOLECULAR-BASIS; AGE; IDENTIFICATION; DEGRADATION; METHYLGLYOXAL; ENDPRODUCTS; PEPTIDES; ACCUMULATION; LENS;
D O I
10.1007/s00216-016-9651-4
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Advanced glycation end products (AGEs) are posttranslational modifications formed non-enzymatically from the reaction of carbohydrates and their degradation products with proteins. Accumulation of AGEs is associated with the progression of severe diabetic complications, for example, and elevated tissue levels of AGEs might even predict these pathologies. As AGE formation is often site-specific, mapping of these modification sites may reveal more sensitive and specific markers than the global tissue level. Here, 42 AGE modifications were identified in a bottom-up proteomic approach by tandem mass spectrometry, which corresponded to 36 sites in 22 high to medium abundant proteins in individual plasma samples obtained from type 2 diabetes mellitus (T2DM) patients with long disease duration (> 10 years). Major modifications were glarg (11 modification sites) and carboxymethylation (5) of arginine and formylation (8), acetylation (7), and carboxymethylation (7) of lysine residues. Relative quantification of these sites in plasma samples obtained from normoglycemic individuals (n = 47) and patients with T2DM being newly diagnosed (n = 47) or of medium (2-5 years, n = 20) and long disease duration (> 10 years, n = 20) did not reveal any significant differences.
引用
收藏
页码:5557 / 5566
页数:10
相关论文
共 50 条
  • [31] Antibodies to advanced glycation end products in children with diabetes mellitus
    Nicoloff, G
    Baydanoff, S
    Petrova, C
    Christova, P
    VASCULAR PHARMACOLOGY, 2002, 39 (1-2) : 39 - 45
  • [32] Advanced Glycation End Products, Bone Health, and Diabetes Mellitus
    Jiang, Jingjing
    Zhao, Changyu
    Han, Tingting
    Shan, Hongyan
    Cui, Guiyou
    Li, Songnan
    Xie, Zhongwen
    Wang, Jun
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2022, 130 (10) : 671 - 677
  • [33] Advanced Glycation End Products Are a Risk for Muscle Weakness in Patients with Type 2 Diabetes
    Mori, Hiroyasu
    Kuroda, Akio
    Araki, Michiko
    Suzuki, Reiko
    Ohishi, Mami
    Taniguchi, Satoshi
    Tamaki, Motoyuki
    Akehi, Yuko
    Sakaue, Hiroshi
    Kurahashi, Kiyoe
    Kondo, Takeshi
    Yoshida, Sumiko
    Endo, Itsuro
    Aihara, Ken Ichi
    Funaki, Makoto
    Matsuhisa, Munehide
    DIABETES, 2017, 66 : A434 - A434
  • [34] Advanced Glycation End Products and Well-Being in Male Subjects with Type 2 Diabetes Mellitus
    Papachristou, S.
    Kazakos, K.
    Moschos, I.
    Papazoglou, D.
    Papanas, N.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2024, 132 (01) : 47 - 48
  • [35] Advanced glycation end products and endothelial dysfunction in type 2 diabetes
    Tan, KCB
    Chow, WS
    Ai, VHG
    Metz, C
    Bucala, R
    Lam, KSL
    DIABETES CARE, 2002, 25 (06) : 1055 - 1059
  • [36] Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes
    Koska, Juraj
    Saremi, Aramesh
    Howell, Scott
    Bahn, Gideon
    De Courten, Barbora
    Ginsberg, Henry
    Beisswenger, Paul J.
    Reaven, Peter D.
    DIABETES CARE, 2018, 41 (03) : 570 - 576
  • [37] Serum level of soluble receptor for advanced glycation end products is associated with circulating advanced glycation end products in type 2 diabetes
    Tan, K. C. B.
    Chow, W. S.
    Shiu, S. W. M.
    Bucala, R.
    Betteridge, D. J.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 294 - 294
  • [38] Therapeutic options to reduce advanced glycation end products in patients with diabetes mellitus: A review
    Jud, Philipp
    Sourij, Harald
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 148 : 54 - 63
  • [39] Increased advanced glycation end products in hypertrophied ligamentum flavum of diabetes mellitus patients
    Maruf, Mohammad Hasib
    Suzuki, Akinobu
    Hayashi, Kazunori
    Habibi, Hasibullah
    Salimi, Hamidullah
    Terai, Hidetomi
    Tamai, Koji
    Hoshino, Masatoshi
    Toyoda, Hiromitsu
    Yamada, Kentaro
    Takahashi, Shinji
    Ohyama, Shoichiro
    Hori, Yusuke
    Nakamura, Hiroaki
    SPINE JOURNAL, 2019, 19 (10): : 1739 - 1745
  • [40] Genetic Variants of the Receptor for Advanced Glycation End-products in Susceptibility to Type 2 Diabetes Mellitus in Primary Hypertensive Patients
    Yang, Hualing
    Nie, Yangyang
    Chen, Zhenyi
    Ye, Linyang
    Wang, Qingxiang
    Wang, Zhanxiang
    SCIENTIFIC REPORTS, 2017, 7